Future Opportunities

1910 Genetics

20n Bio

3DBio Therapeutics

3T Biosciences

4D Molecular Therapeutics

64x Bio

76Bio

8Biomed

A-Alpha Bio

A2 Biotherapeutics

AavantiBio

Ab Studio

Abalone Bio

Abata Therapeutics

Abeona Therapeutics

Abintus Bio

Abiosciences

Absci

Accelevir Diagnostics

Accent Therapeutics

ACELYRIN

Acepodia

Achieve Life Sciences

Acrivon Therapeutics

Acutis Diagnostics

Adaptive Phage Therapeutics

Adcentrx Therapeutics

Adicet Bio

Aditum Bio

adMare BioInnovations

Admera Health

Adverum Biotechnologies

adyn

Aeglea BioTherapeutics

Aether Bio

Affini-T Therapeutics

Affinia Therapeutics

Affinivax

AgBiome

Agena Bioscience

Akero Therapeutics

Akouos

Alamar Biosciences

Alector

AlivaMab Discovery Services

Alkahest

Alladapt Immunotherapeutics

Allakos

Allarta Life Science

Allay Therapeutics

AlloVir

Alloy Therapeutics

Alltrna

AlpaLifeBio

Alpha-9 Theranostics

Alphabioregen

Alpine Immune Sciences

Altis Biosystems

Alto Neuroscience

AltPep

Alumis

Alveo Technologies

Alveolus Bio

ALX Oncology

Alzheon

AmbAgon Therapeutics

Amberstone Biosciences

Amolyt Pharma

Amylyx Pharmaceuticals

AN2 Therapeutics

Anagram Therapeutics

Andes

Angiex

Angiocrine Bioscience

AnHeart Therapeutics

Annexon Biosciences

Anokion

Ansa Biotechnologies

Antheia

Anthos Therapeutics

AOA Dx

Apic Bio

Apollomics

Appia Bio

Applied Molecular Transport

Apriori Bio

Aptevo Therapeutics

Apton Biosystems

Aptose Biosciences

Aquinnah Pharmaceuticals

Aramis Biosciences

Arbor Biotechnologies

Arcadia Science

Arcellx

Arctoris

Arcturus Therapeutics

Arcutis Biotherapeutics

Arima Genomics

Ark Biotech

Arkuda Therapeutics

Foghorn Therapeutics’ Gene Traffic Control platform is designed to target and modulate the chromatin regulatory system. Components of the chromatin regulatory system are synthesized and used for proprietary assays to guide the discovery and optimization of drug targets. High throughput screening of candidate compounds is then used to discover drugs that modulate the chromatin regulatory system. Foghorn currently has multiple therapeutics targeting cancer in Phase 1 clinical trials in addition to therapeutics targeting transcription factors and synthetic lethal targets, among others, in discovery stages. Phase 1 trials are currently enrolling for uveal melanoma, synovial sarcoma, acute myeloid leukemia, and myelodysplastic syndrome.

<p>Foghorn Therapeutics’ Gene Traffic Control platform is designed to target and modulate the chromatin regulatory system. Components of the chromatin regulatory system are synthesized and used for proprietary assays to guide the discovery and optimization of drug targets. High throughput screening of candidate compounds is then used to discover drugs that modulate the chromatin regulatory system.</p>
<p>Foghorn currently has multiple therapeutics targeting cancer in Phase 1 clinical trials in addition to therapeutics targeting transcription factors and synthetic lethal targets, among others, in discovery stages. Phase 1 trials are currently enrolling for uveal melanoma, synovial sarcoma, acute myeloid leukemia, and myelodysplastic syndrome.</p>


Find a biotech startup job.